A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in adults with moderate-to-severe uncontrolled asthma despite controller therapies. 194 subjects were randomised to receive tralokinumab (150, 300 or 600 mg) or placebo subcutaneously every 2 weeks. Primary end-point was change from baseline in mean Asthma Control Questionnaire score (ACQ-6; ACQ mean of six individual item scores) at week 13 comparing placebo and combined tralokinumab dose groups. Secondary end-points included pre-bronchodilator lung function, rescue β 2 -agonist use and safety. Numerical end-points are reported as mean± sd . At week 13, change from baseline in ACQ-6 was -0.76±1.04 for tralokinumab versus -0.61±0.90 for placebo (p=0.375). Increases from baseline in forced expiratory volume in 1 s (FEV 1 ) were 0.21±0.38 L versus 0.06±0.48 L (p=0.072), with a dose-response observed across the tralokinumab doses tested. β 2 -agonist use (puffs per day) was decreased for tralokinumab -0.68±1.45 versus placebo -0.10±1.49 (p=0.020). The increase in FEV 1 following tralokinumab treatment remained evident 12 weeks after the final dose. Safety profile was acceptable with no serious adverse events related to tralokinumab. No improvement in ACQ-6 was observed, although tralokinumab treatment was associated with improved lung function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Requirement for IL-13 Independently of IL-4 in Experimental Asthma
Grünig, G., Warnock, M., Wakil, A. E., Venkayya, R., Brombacher, F., Rennick, D. M., Sheppard, D., Mohrs, M., Donaldson, D. D., Locksley, R. M., et al. (1998) · Science · doi:10.1126/science.282.5397.2261 · Cited by 1,849
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y., & Elias, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5909 · Cited by 1,719
Self-citationLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Juniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.08.012 · Cited by 998
Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment
Peters, S. P., Ferguson, G., Deniz, Y., & Reisner, C. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.03.031 · Cited by 320
Humbert, M., Durham, S. R., Kimmitt, P., Powell, N., Assoufi, B., Pfister, R., Menz, G., Kay, A. B., & Corrigan, C. J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70028-9 · Cited by 314
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Corren, J., Busse, W., Meltzer, E. O., Mansfield, L., Bensch, G., Fahrenholz, J., Wenzel, S. E., Chon, Y., Dunn, M., Weng, H. H., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1448oc · Cited by 299
Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma
Bousquet, J., Wenzel, S., Holgate, S., Lumry, W., Freeman, P., & Fox, H. (2004) · Chest · doi:10.1378/chest.125.4.1378 · Cited by 277
Increased sputum and bronchial biopsy IL-13 expression in severe asthma
Saha, S. K., Berry, M. A., Parker, D., Siddiqui, S., Morgan, A., May, R., Monk, P., Bradding, P., Wardlaw, A. J., Pavord, I. D., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.01.005 · Cited by 255
Self-citationEffects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
Gauvreau, G. M., Boulet, L.-P., Cockcroft, D. W., FitzGerald, J. M., Carlsten, C., Davis, B. E., Deschesnes, F., Duong, M., Durn, B. L., Howie, K. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1210oc · Cited by 230
Blanchard, C., Mishra, A., Saito‐Akei, H., Monk, P., Anderson, I., & Rothenberg, M. E. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02299.x · Cited by 181
Extent, patterns, and burden of uncontrolled disease in severe or difficult‐to‐treat asthma
Sullivan, S. D., Rasouliyan, L., Russo, P. A., Kamath, T., Chipps, B. E., & for the TENOR Study Group (2007) · Allergy · doi:10.1111/j.1398-9995.2006.01254.x · Cited by 181
GRUNSTEIN, M. M., Hakonarson, H. H., Leiter, J., Chen, M., Whelan, R. S., Grunstein, J. S., & Chuang, S. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00343.2001 · Cited by 168
IL‐13 enhances agonist‐evoked calcium signals and contractile responses in airway smooth muscle
Tliba, O., Deshpande, D., Chen, H., Van Besien, C., Kannan, M., Panettieri, R. A., & Amrani, Y. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705558 · Cited by 160
Guilbert, T. W., Garris, C., Jhingran, P., Bonafede, M., Tomaszewski, K. J., Bonus, T., Hahn, R. M., & Schatz, M. (2011) · Journal of Asthma · doi:10.3109/02770903.2010.535879 · Cited by 142
Modulation of Calcium Signaling by Interleukin-13 in Human Airway Smooth Muscle
Deshpande, D. A., Doğan, S., Walseth, T. F., Miller, S. M., Amrani, Y., Panettieri, R. A., & Kannan, M. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0313oc · Cited by 134
May, R., Monk, P., Cohen, E., Manuel, D., Dempsey, F., Davis, N., Dodd, A., Corkill, D., Woods, J., Joberty‐Candotti, C., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01659.x · Cited by 102
Self-citationSingh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L. K., & Woodcock, A. A. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-3 · Cited by 84
Self-citationHaselkorn, T., Chen, H., Miller, D. P., Fish, J. E., Peters, S. P., Weiss, S. T., & Jones, C. A. (2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.04.006 · Cited by 65
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
Junttila, I. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00888 · Cited by 684
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Metadata
- Authors
- Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., & Molfino, N. A.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2012-06-27
- Volume
- 41
- Issue
- 2
- Pages
- 330-338
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2153395214
- Cited by
- 373
- References
- 23
- FWCI
- 23.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.